Brian Ball, MD, on Higher-Risk MDS: Bexmarilimab and Azacitidine

December 08, 2025 By The ASCO Post Staff

Brian Ball, MD, of City of Hope, presents updated results from the phase I/II BEXMAB study. They showed that the doublet had encouraging activity in patients with TP53-mutant, higher-risk MDS; translational data support the combination regimen’s potential for altering immune dysregulation in this subtype (Abstract 236). 

Related Content